Document Detail

Effect of the Macroplastique Implantation System for stress urinary incontinence in women with or without a history of an anti-incontinence operation.
MedLine Citation:
PMID:  21461709     Owner:  NLM     Status:  Publisher    
INTRODUCTION AND HYPOTHESIS: We evaluated the outcomes and the effect of the Macroplastique Implantation System on the quality of life in women with stress incontinence with or without a history of an anti-incontinence operation during 12 to 62 months follow-up. METHODS: Thirty-five women with urodynamically proven stress incontinence with intrinsic sphincter deficiency were included in this study. Macroplastique injection was performed in all patients. Quality of life was evaluated prior to therapy, in early postoperative time (at the sixth weeks) and in late postoperative time (12 to 62 months follow-up) with the use of three different questionnaires: Incontinence Quality-of-Life Questionnaire (I-QOL), Incontinence Impact Questionnaire-7 (IIQ-7), and Urogenital Distress Inventory-6 (UDI-6). Questionnaires were also compared with those previous to the anti-incontinence operation and to the primary procedure groups. RESULTS: The median age of the women was 50.00 (interquartile range = 17.00) years. There were 24 primary procedures and 11 had undergone previous anti-incontinence surgery. Maximum follow-up time was 62 months, minimum follow-up time was 12 months, and the median follow-up time of the study was 58 (interquartile range = 44-60) months. When preoperative and postoperative median of the I-QOL, IIQ-7, and UDI-6 scores were compared, the differences between scores were found to be statistically significant. I-QOL, IIQ-7, and UDI-6 scores were related to the previous surgery. The overall I-QOL, IIQ-7, and UDI-6 summary scores showed high internal consistency. CONCLUSIONS: The Macroplastique injection system is an effective, safe, and acceptable option for stress urinary incontinence in women with or without a history of an anti-incontinence operation. Moreover, it can be performed under local anesthesia without cystoscopic guidance; moreover, side effects are rare.
Ilknur Inegol Gumus; Ikbal Kaygusuz; Aysel Derbent; Serap Simavli; Hasan Kafali
Related Documents :
17383459 - Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis a...
23248229 - Antibiotic prophylaxis for urinary tract infections in antenatal hydronephrosis.
25126629 - Patients perceptions of recovery after maxillary sinus augmentation with a minimally in...
23140829 - Long-term results and quality of life in patients treated with hemorrhoidectomy using t...
23566699 - Total hip arthroplasty in young females with congenital dislocation of the hip, radical...
21482369 - Is transobturator suburethral sling effective for treating female urodynamic stress inc...
3272249 - Our experiences in surgical treatment of thoracic echinococcosis during the period 1977...
8068589 - Patient-controlled sedation using midazolam.
20731479 - Octreotide long-acting release (lar): a review of its use in the management of acromegaly.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-4-2
Journal Detail:
Title:  International urogynecology journal and pelvic floor dysfunction     Volume:  -     ISSN:  1433-3023     ISO Abbreviation:  -     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-4-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9514583     Medline TA:  Int Urogynecol J Pelvic Floor Dysfunct     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Obstetrics and Gynecology, Fatih University School of Medicine, Ciftlik Cad. No: 57, 06510, Emek, Ankara, Turkey,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  "J" cut of sling for postoperative voiding dysfunction following synthetic midurethral slings.
Next Document:  Functional myogenic engraftment from mouse iPS cells.